A detailed history of Capital International Sarl transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital International Sarl holds 102,985 shares of GILD stock, worth $9.62 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
102,985
Previous 85,225 20.84%
Holding current value
$9.62 Million
Previous $5.85 Million 47.63%
% of portfolio
0.23%
Previous 0.19%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$66.59 - $83.99 $1.18 Million - $1.49 Million
17,760 Added 20.84%
102,985 $8.63 Million
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $313,287 - $361,557
4,961 Added 6.18%
85,225 $5.85 Million
Q1 2024

May 14, 2024

BUY
$71.58 - $87.29 $776,643 - $947,096
10,850 Added 15.63%
80,264 $5.88 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $824,653 - $935,177
11,255 Added 19.35%
69,414 $5.62 Million
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $1.63 Million - $1.78 Million
22,025 Added 60.95%
58,159 $4.36 Million
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $2.75 Million - $3.13 Million
36,134 New
36,134 $2.78 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $34,295 - $39,173
-576 Reduced 7.74%
6,865 $424,000
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $277,690 - $312,763
-4,811 Reduced 39.27%
7,441 $460,000
Q1 2022

May 16, 2022

SELL
$57.92 - $72.58 $3.64 Million - $4.56 Million
-62,812 Reduced 83.68%
12,252 $728,000
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $314,862 - $357,374
-4,853 Reduced 6.07%
75,064 $5.45 Million
Q3 2021

Nov 15, 2021

SELL
$67.69 - $73.03 $206,251 - $222,522
-3,047 Reduced 3.67%
79,917 $5.58 Million
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $294,627 - $321,922
4,642 Added 5.93%
82,964 $5.71 Million
Q1 2021

May 14, 2021

SELL
$60.0 - $68.46 $576,780 - $658,105
-9,613 Reduced 10.93%
78,322 $5.06 Million
Q4 2020

Feb 16, 2021

BUY
$56.65 - $64.55 $22,773 - $25,949
402 Added 0.46%
87,935 $5.12 Million
Q3 2020

Nov 16, 2020

SELL
$62.1 - $78.08 $1.37 Million - $1.72 Million
-22,046 Reduced 20.12%
87,533 $5.53 Million
Q2 2020

Aug 14, 2020

BUY
$72.34 - $84.0 $1.41 Million - $1.64 Million
19,543 Added 21.71%
109,579 $8.43 Million
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $3.13 Million - $4.01 Million
49,929 Added 124.49%
90,036 $6.73 Million
Q4 2019

Feb 18, 2020

BUY
$61.62 - $67.78 $48,186 - $53,003
782 Added 1.99%
40,107 $2.61 Million
Q3 2019

Nov 14, 2019

BUY
$62.51 - $69.0 $2.46 Million - $2.71 Million
39,325 New
39,325 $2.49 Million
Q1 2019

May 15, 2019

SELL
$62.53 - $70.05 $844,155 - $945,675
-13,500 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$60.54 - $79.0 $563,022 - $734,700
-9,300 Reduced 40.79%
13,500 $844,000
Q3 2018

Nov 14, 2018

SELL
$71.28 - $78.92 $719,928 - $797,092
-10,100 Reduced 30.7%
22,800 $0
Q2 2018

Aug 14, 2018

SELL
$64.88 - $75.68 $45,416 - $52,976
-700 Reduced 2.08%
32,900 $2.33 Million
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $7,284 - $8,880
-100 Reduced 0.3%
33,600 $2.53 Million
Q4 2017

Feb 14, 2018

SELL
$71.15 - $83.52 $579,872 - $680,688
-8,150 Reduced 19.47%
33,700 $2.41 Million
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $3.02 Million - $3.58 Million
41,850
41,850 $3.39 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $117B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Capital International Sarl Portfolio

Follow Capital International Sarl and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Sarl with notifications on news.